Vol 57, No 4 (2006)
Review paper
Published online: 2006-07-07
Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer - update of current and our own experiences
Endokrynol Pol 2006;57(4):445-451.
Abstract
Traditionally, for diagnostic and therapeutic application of
radioiodine in patients with differentiated thyroid cancer
(DTC), a 4 to 6 week withdrawal of thyroid hormone was
applied. Recombinant human TSH (rhTSH) was developed
to provide TSH stimulation without withdrawal of thyroid
hormone and associated morbidity. The results of rhTSH
administration and endogenous TSH stimulation are equivalent
in detecting recurrent DTC. At the present time
rhTSH is approved as an adjunct for diagnostic procedures
and thyroid ablation in patients with DTC. In addition,
rhTSH has potential for use in facilitating the treatment of
metastases in patients with DTC.
In this review we have summarized our own experiences
with rhTSH aided radioiodine therapy in patients with disseminated
thyroid cancer. Generally, rhTSH was very well tolerated and treatment results were comparable to those
achieved with thyroid hormone withdrawal.
Keywords: differentiated thyroid cancerrhTSHradiodine treatment
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)